SERUM VITAMIN B12 LEVELS IN PATIENTS WITH HEMORRHAGIC VS ISCHEMIC CEREBROVASCULAR EVENT.

NCT06190314 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-01-05

No results posted yet for this study

Summary

Cerebral vascular events (CVA) have a high prevalence in our environment; they are the first cause of disability and the second cause of death in the world (6.6 million deaths). 71% of all strokes worldwide correspond to the ischemic type, which is defined as an infarction in the brain, spinal cord or retina; The remaining 10-40% are hemorrhagic and are due to rupture of cerebral arteries. Until epidemiological week 35 of 2022, 34,643 cases were reported in Mexico, for this week in 2021, 26,462 cases had been reported. Baja California is among the first three places in the country with the highest number of reported cases, the majority corresponding to the male sex. The key clinical characteristic is the sudden appearance of a focal neurological deficit. Imaging studies such as head computed tomography or magnetic resonance imaging allow us to differentiate the subtype and mechanism of CVD since treatment differs markedly between CVD of ischemic origin and that of hemorrhagic origin. Vitamin B12 or cobalamin is a tetrapyrrole cofactor; One of its functions is to participate in the metabolism of homocysteine, which has been reported in various studies and it has been shown that high levels of this increase the risk of vascular diseases, such as stroke. On the other hand, vitamin B12 deficiency can lead to platelet dysfunction, causing significant bleeding. There are few protocols that have sought the direct association of cobalamin with CVD and even fewer with the hemorrhagic type. This condition is one of the main causes of admission to the Emergency Service of the General Hospital of Mexicali where they are given the necessary attention such as performing imaging studies and taking laboratory samples and based on the results the treatment to be followed is decided; However, measurements of vitamin B12 levels are not performed in this population. If the association is demonstrated, it could be implemented as a preventive measure for cerebral vascular events.

Conditions

Interventions

DIAGNOSTIC_TEST

Measure serum vitamin b12 levels

Measure the vitamin b-12 levels in patients that are admitted for stroke of any kind

Sponsors & Collaborators

  • Sandoval Briones Jocelin Lisset

    collaborator UNKNOWN
  • Hirata Medina Nancy Midory

    collaborator UNKNOWN
  • Felix Escobedo Marisol

    collaborator UNKNOWN
  • Cervantes De Carlos Cereza Guadalpe

    collaborator UNKNOWN
  • Aceves Lozano Natalia

    collaborator UNKNOWN
  • Cota Andara Manuel Eduardo

    collaborator UNKNOWN
  • Avila Pacheco Manlio Abraham

    collaborator UNKNOWN
  • Rodriguez Gonzalez Alondra

    collaborator UNKNOWN
  • Barruquin Sandoval Claudia Pamela

    collaborator UNKNOWN
  • González Gómez René Ignacio

    collaborator UNKNOWN
  • Jaramillo Ramirez Hiram Javier.

    collaborator UNKNOWN
  • Hospital General de Mexicali

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-13
Primary Completion
2024-07-01
Completion
2024-11-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06190314 on ClinicalTrials.gov